Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Every story we pull is tagged to the disease it’s about — so you can filter to your condition and read only what matters.
20 earlier
AbbVie is eyeing regulatory filings in 2027 for the skin disease drug lutikizumab after clearing multiple endpoints in a late-stage trial, but the results have disappointed some analysts, raising questions about its commercial prospects.
Original title: “AbbVie’s skin disease drug lessens abscess burden in Phase 3 but falls below expectations”
On October 3, 2026, families from across the country gathered in Novato, California, for Rare Family Day, a Star Wars-themed celebration hosted by Ultragenyx, a biopharmaceutical company focused on developing […]
Original title: “Rare Family Day 2026: The Power of Community ”
A combination of the shot and the immunotherapy Keytruda cut the risk of relapse or death by 42% in a landmark melanoma study that met Wall Street expectations but triggered a “sell-the-news reaction,” one analyst wrote.
Original title: “Moderna, Merck shares fall on eagerly anticipated cancer vaccine results”
FDA announces the launch of the Neuroscience Advancement and Innovation Nexus (NAIN), a new agency program aligned with the Trump Administration’s efforts to accelerate medical innovation and deliver breakthrough treatments.
Original title: “FDA Launches New Program to Advance Neuroscience Medical Product Development ”
U.S. regulators have accepted a new submission for Vyglxia, offering the chance at a turnaround for another rare disease medicine spurned by previous FDA leadership.
Original title: “Biohaven’s previously rejected rare disease drug to get fresh FDA review”
The notice adds to growing concerns about the safety of knockoff weight loss drugs, which have remained popular despite FDA warnings and legal pressure from Eli Lilly and Novo.
Original title: “GLP-1 compounder issues recall for copycat Zepbound”
Troriluzole, in development for spinocerebellar ataxia, was rejected nearly a year ago when the FDA took issue with the design of Biohaven’s registrational study. The agency has now agreed to review a new application and render a decision in the first quarter of 2027.
Original title: “Biohaven shares pop as FDA accepts resubmission for ataxia drug with adcomm expected”
Lower-than-expected sales of Xolair stood out as the Swiss drugmaker readies for an onslaught of generic competition for top products.
Original title: “Roche affirms sales outlook amid doubts about its future”
The approval of Hibsago has created a new market for a handful of biopharmas, including Gilead, Arrowhead, and Vir, to fill in.
Original title: “GSK, Ionis hepatitis B functional cure breaks open market for followers”
Aside from RG6540, Roche also discontinued a host of other early-stage assets, including an antisense oligonucleotide for Alzheimer’s disease and a small-molecule candidate for geographic atrophy.
Original title: “Roche’s pipeline trim claims Poseida’s off-the-shelf CAR T asset”
In this episode of Denatured, you’ll hear from Bruce Culleton, CEO at ProKidney and Demetri Maxim, CEO at Nephrogen. We discuss why kidney disease has long been a hard target for cell and gene therapies, and what new delivery strategies, therapeutic approaches and regulatory clarity mean for commercially viable products.
Original title: “Why investors are taking another look at kidney disease”